Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma

<p>Cancer immunotherapy has emerged as an important therapeutic modality in preclinical and clinical oncology. Blocking inhibitory signaling and engaging stimulatory signaling enable some patients to produce an efficient antitumor response. In this work, we demonstrate unique and unexpected immunomodulatory features of different costimulatory ligand proteins with no combination of tumor-associated products, which bridge innate and adaptive immune responses against cancer in preventive as well as therapeutic efficacy.</p>